Corporate Presentation Corporate Presentation R&D Day 2024 R&D Day 2024 IIGANN 2023 Sponsored Symposium Targeting the Source of IgA Nephropathy ASN 2023 Presentations ORIGIN 3: Pivotal Phase 3 Study Evaluating Effect of Atacicept vs Placebo on Proteinuria and Renal Function Preservation in IgAN Atacicept Reduces Hematuria and Serum Gd-IgA1, Both Associated with Long-term Renal Outcomes in IgAN: 36 Week Results from the Phase 2b ORIGIN Study Atacicept in IgAN: Continued Protective Titers to Diphtheria and Tetanus and Balanced Infections vs Placebo with a Focus on COVID-19 ERA 2023 Late Breaking Presentation 36-Week Efficacy & Safety of Atacicept 150 mg in the ORIGIN Randomized, Double-blind, Placebo-controlled Phase 2b Study in IgAN and Persistent Proteinuria ASN 2022 Presentations Atacicept Reduces Serum Immune Complex Levels in IgAN Patients A Randomized Phase 2 Study of MAU868 vs Placebo to Treat BK Viremia in Kidney Transplant Recipients – Week 36 Results ERA EDTA 2022 Presentations 2022 ERA EDTA anti GdlgA1 2022 ERA EDTA April SLE Renal ASN 2021 E-Poster Presentation Atacicept Reduces Serum Gd-IgA1 by Quartiles in IgAN Patients Investor Calendar and Recordings
ORIGIN 3: Pivotal Phase 3 Study Evaluating Effect of Atacicept vs Placebo on Proteinuria and Renal Function Preservation in IgAN
Atacicept Reduces Hematuria and Serum Gd-IgA1, Both Associated with Long-term Renal Outcomes in IgAN: 36 Week Results from the Phase 2b ORIGIN Study
Atacicept in IgAN: Continued Protective Titers to Diphtheria and Tetanus and Balanced Infections vs Placebo with a Focus on COVID-19
36-Week Efficacy & Safety of Atacicept 150 mg in the ORIGIN Randomized, Double-blind, Placebo-controlled Phase 2b Study in IgAN and Persistent Proteinuria
A Randomized Phase 2 Study of MAU868 vs Placebo to Treat BK Viremia in Kidney Transplant Recipients – Week 36 Results
